key: cord-0742540-xvh6xnnx authors: Baek, Yae Jee; Lee, Youn-Jung; Kim, Jae In; Lee, Seju; Kim, Jinnam; Lee, Eun Hwa; Lee, Ki Hyun; Kim, Jung Ho; Ahn, Jin Young; Jeong, Su Jin; Ku, Nam Su; Yeom, Joon-Sup; Choi, Jun Yong title: Prolonged viral shedding in severely ill patients infected with SARS-CoV-2 Delta variants: a retrospective cohort study date: 2022-04-05 journal: J Infect DOI: 10.1016/j.jinf.2022.04.003 sha: 778f298a3b7fc1f72c317fadcf61b0cdb2f50b24 doc_id: 742540 cord_uid: xvh6xnnx nan Non-pharmaceutical interventions (NPIs) and vaccination programs have played crucial roles in mitigating a novel coronavirus disease 2019 (COVID-19) pandemic. The isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected individuals is one of the important and effective NPIs (1) . Many studies revealed that patients with mild-tomoderate illness confirmed with SARS-CoV-2 could not be infectious beyond 10 days after symptom onset (2) . Therefore, the guidelines were published for releasing COVID-19 patients from isolation 10 days after symptom onset, plus at least 3 additional days without symptoms. For severely ill COVID-19 patients, extending the duration of isolation and precautions up to 20 days after symptom onset and after resolution of fever and improvement of other symptoms may be warranted. The emergence of SARS-CoV-2 variants of concern (VOCs) harboring mutations in the spike (S) protein has raised concerns about higher transmissibility and potential immune escape after vaccination and natural infection. The B.1.617.2 (delta) variant was detected in India in December 2020. New variants and SARS-CoV-2 vaccination strategies may influence the duration of viable virus shedding in confirmed patients (3) . In addition, corticosteroid and interleukin (IL)-6 blockade, tocilizumab, which have been recommended regimens in severe patients, may be associated with prolonged viral shedding (4). Therefore, any recommendations which use a fixed number of days should incorporate various influences on viral shedding such as host susceptibility, vaccination status, and virus strains. In addition, more studies are needed to fully understand virus transmission related to the delta variant among severe patients. Since virus culture is important to assess the viability, and could be a surrogate for transmissibility, we aimed to identify the transmissibility of SARS-CoV-2 in severe patients who were infected with the delta variant in comparison to the original virus (Wuhan-hu-1). Twenty-six patients who were hospitalized and diagnosed with delta variant infections between June and August 2021 were consecutively enrolled as the delta variant cohort. The cohort was compared to the original strain cohort, which comprised twenty-one original virus-infected patients who were consecutively hospitalized between February and June 2020. It was a single center cohort study at a referral hospital where COVID-19 patients at higher risk of severe infection were transferred, and antiviral therapy as well as other medication, including immunomodulator, was administered based on the guideline available at the time and clinical judgement. Our team has previously reported the result of the original virus culture to suggest the duration of transmissibility of the virus (5) . According to the study, samples from patients with original virus were collected 1, 3, 5, 7, 10, and 14 days after admission. In delta variant patients, samples from nasopharyngeal (NP) swabs and sputum were obtained at times decided by an attending physician. The study was approved by the Institutional Review Board of Severance Hospital (4-2020-0076) and written informed consent was obtained from all subjects. We defined severity of the COVID-19 infection that mild patients required hospitalization without oxygen therapy, moderate patients required low flow oxygen therapy, severe patients required high-flow oxygen therapy, and critically ill patients required mechanical ventilation or extracorporeal membrane oxygenation. The methods of confirmation, identification and culture of SARS-CoV-2 methods were described in Supplementary method. In the delta variant cohort, the patients whose samples were collected beyond 14 days was further divided in two groups: "late clearance (LC)" group which is defined as virus culture positive beyond 14 days after symptom onset and "early clearance (EC)" whose samples In ad hoc analysis of the delta variant group, the demographics of both LC and EC group is described in Table 1 . All patients received steroid and IL-6 blockade, and the doses of corticosteroid were similar in both groups. In the LC group, critically ill patients represented half of the patients, but the severity between groups did not show statistical differences. The median age in the LC group was significantly higher than that in the EC group (p<0.001) and female has high portion in the LC group (p=0.014). Epidemiologic studies show that the delta variant might be more virulent, increasing risk of hospitalization, intensive care unit (ICU) admission, and death (6) . In our study, most of the delta variant-infected patients had received critical care in ICU, ten of whom needed ventilation support and three, extracorporeal membrane oxygenation. They produced more proportion of replicationcompetent virus than original virus-infected patients beyond 10 days after symptom onset A recent study suggested SARS-CoV-2 viral dynamics for some VOCs, indicating that peak Ct was lower, but posterior trajectories had higher proportions of Ct count less than 15 in the delta variant compared to the original or other variant of SARS-CoV-2 (7). Other study revealed that individual infections during which viral replication is initially fastest generate the highest peak viral load and see the slowest viral clearance, but vaccinations accelerate viral clearance (3). In our study, only three patients received partial vaccination (primer dose of vaccination), so other factors such as strains, medication could impact the viral clearance. Although interleukin (IL)-6 blockade is associated with clinical improvements for COVID-19 patients (8) , it could suppress pathogenic T-cells and inflammatory monocytes, while inducing a reduction in the peripheral memory B cells and suppressing the viral clearance (4). Therefore, compromised immunity due to immunomodulatory combination therapy for severe infection may allow the virus to continually replicate and progressively accrue genetic diversity (9) . In addition, older age and female are related to prolonged viral shedding in subsequent analysis, which is consistent with the previous results and difference in immune responses to the infection (10) . In fact, some severe patients confirmed with delta variant have prolonged viral shedding regardless of viral load of the samples, indicating that Ct values would not be specific for viability of the delta variant SARS-CoV-2. One limitation of our study is, since it is an observational cohort study, two separate cohorts show different baseline characteristics, which are not comparable to analyze. In addition, the HI14C1324), and the 2020 Joint Research Project of Institutes of Science and Technology Revisiting the guidelines for ending isolation for COVID-19 patients The duration of infectiousness of individuals infected with SARS-CoV-2 Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection Duration of culturable SARS-CoV-2 within different specimens among mild and severe COVID-19 patients: A longitudinal study Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis Accelerating the Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: A Risk of Combining Dexamethasone and Tocilizumab for Severe Coronavirus Disease Prolonged viral shedding of SARS-CoV-2 and related factors in symptomatic COVID-19 patients: a prospective study The authors declare no conflict of interest.